Skip to main content
SpringerLink
Log in

Les anti-TNF dans la polyarthrite rhumatoïde

  • Chapter
Biothèrapies en rhumatologie

  • 264 Accesses

Résumé

La polyarthrite rhumatoide (PR) est l’exemple-type de maladie inflammatoire dans laquelle le facteur nécrosant des tumeurs-alpha (TNF-α) joue un role majeur. L’utilisation de molécules anti-TNF-α dans le traitement de la PR date de 1993, et la plupart des connaissances accumulées sur ces agents proviennent donc de leur utilisation dans cette pathologie.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Maini R, St Clair EW, Breedveld F et al. (1999) Infliximab (chimeric anti-tumournecrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932–9

    Article  CAS  Google Scholar 

  2. Lipsky PE, van der Heijde DM, St Clair EW et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594–602

    Article  PubMed  CAS  Google Scholar 

  3. Breedveld FC, Han C, Bala M et al. (2005 ) Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis. Ann Rheum Dis 64: 52–5

    Article  PubMed  CAS  Google Scholar 

  4. Breedveld FC, Emery P, Keystone E et al. (2004) Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63: 149–55

    Article  PubMed  CAS  Google Scholar 

  5. Smolen JS, Han C, Bala M et al. (2005) Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52: 1020–30

    Article  PubMed  CAS  Google Scholar 

  6. St Clair EW, van der Heijde DM, Smolen JS et al. (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50: 3432–43

    Article  PubMed  CAS  Google Scholar 

  7. Smolen JS, Van Der Heijde DM, St Clair EW et al. (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54:702–10

    Article  PubMed  CAS  Google Scholar 

  8. Klareskog L, van der Heijde D, de Jager JP et al. (2008) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675–81

    Google Scholar 

  9. Van der Heijde D, Klareskog L, Rodriguez-Valverde V et al. (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54:1063–74

    Article  PubMed  Google Scholar 

  10. Van der Heijde D, Klareskog L, Landewe R et al. (2007) Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56: 3928–39

    Article  PubMed  Google Scholar 

  11. Genovese MC, Bathon JM, Martin RW et al. (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443–50

    Article  PubMed  CAS  Google Scholar 

  12. Weinblatt ME, Keystone EC, Purst DE et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45

    Article  PubMed  CAS  Google Scholar 

  13. Weinblatt ME, Keystone EC, Purst DE et al. (2006) Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 65: 753–9

    Article  PubMed  CAS  Google Scholar 

  14. Keystone EC, Kavanaugh AF, Sharp JT et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400–11

    Article  PubMed  CAS  Google Scholar 

  15. Breedveld PC, Weisman MH, Kavanaugh AF et al. (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37

    Article  PubMed  CAS  Google Scholar 

  16. Kimel M, Cifaldi M, Chen N, Revicki D (2008) Adalimumab plus methotrexate improved SP-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 35:206–15

    PubMed  CAS  Google Scholar 

  17. Bejarano V, Quinn M, Conaghan PC et al. (2008) Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59:1467–74

    Article  PubMed  Google Scholar 

  18. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52: 3381–90

    Article  PubMed  CAS  Google Scholar 

  19. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Alkart CF et al. (2008) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 58(2 Suppl): S126–35

    PubMed  CAS  Google Scholar 

  20. Van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP et al. (2007) Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 66:1356–62

    Article  PubMed  Google Scholar 

  21. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP et al. (2008) Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 67: 823–8

    Article  PubMed  CAS  Google Scholar 

  22. Emery P, Breedveld PC, Hall S et al. (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372: 375–82

    Article  PubMed  CAS  Google Scholar 

  23. Van VoUenh oven RF, Ernestam S, Geborek P et al. (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 374: 459–66

    Article  Google Scholar 

  24. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I (2005) Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev: CD005113

    Google Scholar 

  25. Smitten AL, Simon TA, Hochberg MC, Suissa S (2008) A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10: R45

    Article  PubMed  Google Scholar 

  26. Baecklund E, Ekbom A, Sparen (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Bmj; 317:180–1

    Article  PubMed  CAS  Google Scholar 

  27. Kaiser R (2008) Incidence of lymphoma in patients with rheumatoid arthritis: a systematic review of the literature. Clin Lymphoma Myeloma 8: 87–93.

    Article  PubMed  Google Scholar 

  28. Bongartz T, Sutton AJ, Sweeting MJ et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama 295:2275–85

    Article  PubMed  CAS  Google Scholar 

  29. Costenbader KH, Glass R, Cui J, Shadick N (2006) Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. Jama 296:2201; author reply 2203-4

    Article  PubMed  CAS  Google Scholar 

  30. Bongartz T, Warren FC, Mines D et al. (2009) Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 68:1177–83

    Article  PubMed  CAS  Google Scholar 

  31. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56:2886–95

    Article  PubMed  Google Scholar 

  32. Askling J, Fored CM, Baecklund E et al. (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64:1414–20

    Google Scholar 

  33. Askling J, Fored CM, Brandt L et al. (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64:1421–6

    Article  PubMed  CAS  Google Scholar 

  34. Dixon WG, Symmons DP, Lunt M et al. (2007) Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 56:2896–904.

    Article  PubMed  CAS  Google Scholar 

  35. Leombruno JP, Einarson TR, Keystone EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68:1136–45

    Article  PubMed  CAS  Google Scholar 

  36. Keane J, Gershon S, Wise RP et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–104

    Article  PubMed  CAS  Google Scholar 

  37. Tubach F, Salmon D, Ravaud P et al. (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60:1884–94

    Article  PubMed  CAS  Google Scholar 

  38. Wallis RS (2008) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8: 601–11

    Article  PubMed  CAS  Google Scholar 

  39. Plessner HL, Lin PL, Kohno T et al. (2007) Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 195:1643–50

    Article  PubMed  CAS  Google Scholar 

  40. Strangfeld A, Listing I, Herzer P et al. (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. Jama 301: 737–44

    Article  PubMed  CAS  Google Scholar 

  41. Miceli-Richard C, Gestermann N, Amiel C et al. (2009) Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies. Arthritis Res Ther 11: R77

    Article  PubMed  Google Scholar 

  42. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S (2005) Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 64: 403–7

    Article  PubMed  CAS  Google Scholar 

  43. Carmona L, Descalzo MA, Perez-Pampin E etal. (2007) All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66: 880–5

    Google Scholar 

  44. Grigor C, Capell H, Stirling A et al. (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263–9

    Article  PubMed  Google Scholar 

  45. Vastesaeger N, Xu S, Aletaha D et al. (2009) A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 48:1114–21

    Article  CAS  Google Scholar 

  46. Kievit W, Fransen I, Oerlemans AI et al. (2007) The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 66:1473–8

    Article  PubMed  CAS  Google Scholar 

  47. Mierau M, Schoels M, Gonda G et al. (2007) Assessing remission in clinical practice. Rheumatology 46: 975–9

    Google Scholar 

  48. Aletaha D, Funovits I, Keystone EC, Smolen IS (2007) Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56: 3226–35

    Article  PubMed  CAS  Google Scholar 

  49. Radstake TR, Svenson M, Eijsbouts AM et al. (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68:1739–45

    Article  PubMed  CAS  Google Scholar 

  50. Karlsson JA, Kristensen LE, Kapetanovic MC et al. (2008) Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 47: 507–13

    Article  PubMed  CAS  Google Scholar 

  51. Smolen JS, Weinblatt ME (2008) When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? Ann Rheum Dis 67:1497–8

    Article  PubMed  Google Scholar 

  52. Bombardieri S, Ruiz AA, Fardellone P et al. (2007) Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 46:1191–9

    Article  PubMed  CAS  Google Scholar 

  53. Buch MH, Bingham SJ, Bejarano V et al. (2007) Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 57:448–53

    Article  PubMed  CAS  Google Scholar 

  54. Hyrich KL, Lunt M, Watson KD et al. (2007) Outcomes after switching from one antitumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13–20

    Article  PubMed  CAS  Google Scholar 

  55. Askling J, Fored CM, Brandt L et al. (2007) Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66:1339–44

    Article  PubMed  Google Scholar 

  56. Radstake TR, Svenson M, Eijsbouts AM et al. (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68:1739–45

    Article  PubMed  CAS  Google Scholar 

  57. Buch MH, Marzo-Ortega H, Bingham SJ, Emery P (2004) Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals. Rheumatology 43:243–4.

    Article  PubMed  CAS  Google Scholar 

  58. Quinn MA, Conaghan PC, O’Connor PJ et al. (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52:27–35

    Article  PubMed  CAS  Google Scholar 

  59. Delavallee L, Le Buanec H, Bessis N et al. (2008) Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 67:1332–8

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. L. Semerano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X. Guillot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M.-C. Boissier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Semerano, L., Guillot, X., Boissier, MC. (2011). Les anti-TNF dans la polyarthrite rhumatoïde. In: Biothèrapies en rhumatologie. Springer, Paris. https://doi.org/10.1007/978-2-8178-0124-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0124-7_3

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0123-0

  • Online ISBN: 978-2-8178-0124-7

Publish with us

Policies and ethics

Search

Navigation